Physician profile
Tyler Cole
NPI 1982086369
$4,223.17
in general payments reported to CMS, 2019-2025
29 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $248 · 2023: $757 · 2024: $1,468 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.50 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $690.02 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $484.37 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $348.45 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $314.88 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Alkermes, INC. | $260.82 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
| Novo Nordisk INC | $232.63 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $202.90 | 2023-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $192.40 | 2021-2024 | Farxiga |
| Amgen INC. | $187.08 | 2024-2025 | Otezla, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $172.30 | 2024-2025 | Fanapt |
| Boston Scientific Corporation | $164.26 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Genzyme Corporation | $123.08 | 2022 | |
| Paratek Pharmaceuticals, INC. | $118.11 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $98.41 | 2023-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.08 | 2023-2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $60.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.36 | 2024-2025 | Jardiance |
| Dexcom, INC. | $59.15 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $58.00 | 2023 | Venaseal |
| Bausch Health US, LLC | $51.50 | 2024-2025 | Aplenzin, Wellbutrin |
| Pfizer INC. | $46.00 | 2023-2025 | |
| Abbott Laboratories | $41.88 | 2024-2025 | Freestyle Libre, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $40.49 | 2023-2025 | |
| Exact Sciences Corporation | $37.04 | 2025 | The Cologuard Plus Collection Kit |
| Noven Therapeutics, LLC | $21.04 | 2024 | Secuado, Xelstrym |
| Masimo Corporation | $20.60 | 2023 | Emma and Isa |
| Xeris Pharmaceuticals, INC. | $19.65 | 2021 | |
| Inspire Medical Systems, INC. | $15.99 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.